Shandong Sito Bio-technology Co Ltd Total Assets
Shandong Sito Bio-technology Co Ltd total assets. Based on the latest financial reports, Shandong Sito Bio-technology Co Ltd (300583) holds total assets worth CN¥2.95 Billion CNY (≈ $432.38 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Shandong Sito Bio-technology Co Ltd worth for the company's overall valuation and market capitalisation.
Total Assets of Shandong Sito Bio-technology Co Ltd (2012–2025)
Total assets of Shandong Sito Bio-technology Co Ltd from 2012 to 2025. This chart illustrates how Shandong Sito Bio-technology Co Ltd's total assets have evolved over time, based on quarterly financial data. See Shandong Sito Bio-technology Co Ltd stock quote for real-time trading data and today's change.
Shandong Sito Bio-technology Co Ltd - Asset Composition Analysis
Shandong Sito Bio-technology Co Ltd Total Assets Breakdown (December 2025)
Shandong Sito Bio-technology Co Ltd total assets breakdown as of December 2025. Shandong Sito Bio-technology Co Ltd's total assets of CN¥2.95 Billion consist of 43.5% current assets and 56.5% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 10.0% |
| Accounts Receivable | CN¥261.62 Million | 8.9% |
| Inventory | CN¥477.24 Million | 16.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥182.86 Million | 6.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Shandong Sito Bio-technology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Shandong Sito Bio-technology Co Ltd working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Sito Bio-technology Co Ltd's current assets represent 43.5% of total assets in 2025, a decrease from 52.7% in 2012.
- Cash Position: Cash and equivalents constituted 10.0% of total assets in 2025, up from 0.1% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 19.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 16.2% of total assets.
Shandong Sito Bio-technology Co Ltd Competitors by Total Assets
Key competitors of Shandong Sito Bio-technology Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Shandong Sito Bio-technology Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.26 | 1.23 | 1.05 |
| Quick Ratio | 0.81 | 0.72 | 0.58 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥263.67 Million | CN¥234.00 Million | CN¥57.82 Million |
Shandong Sito Bio-technology Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shandong Sito Bio-technology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.39 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -2.3% |
| Total Assets | CN¥2.96 Billion |
| Market Capitalization | $305.91 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Sito Bio-technology Co Ltd's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Shandong Sito Bio-technology Co Ltd's assets decreased by 2.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Shandong Sito Bio-technology Co Ltd (2012–2025)
The table below shows the annual total assets of Shandong Sito Bio-technology Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.96 Billion ≈ $432.50 Million |
-2.32% |
| 2024-12-31 | CN¥3.03 Billion ≈ $442.77 Million |
-6.62% |
| 2023-12-31 | CN¥3.24 Billion ≈ $474.15 Million |
+8.18% |
| 2022-12-31 | CN¥3.00 Billion ≈ $438.28 Million |
+0.86% |
| 2021-12-31 | CN¥2.97 Billion ≈ $434.56 Million |
+4.52% |
| 2020-12-31 | CN¥2.84 Billion ≈ $415.77 Million |
-4.89% |
| 2019-12-31 | CN¥2.99 Billion ≈ $437.13 Million |
+15.14% |
| 2018-12-31 | CN¥2.59 Billion ≈ $379.65 Million |
+28.15% |
| 2017-12-31 | CN¥2.02 Billion ≈ $296.26 Million |
+116.25% |
| 2016-12-31 | CN¥936.23 Million ≈ $137.00 Million |
+11.68% |
| 2015-12-31 | CN¥838.28 Million ≈ $122.67 Million |
+65.30% |
| 2014-12-31 | CN¥507.11 Million ≈ $74.21 Million |
+140.73% |
| 2013-12-31 | CN¥210.66 Million ≈ $30.83 Million |
+251.20% |
| 2012-12-31 | CN¥59.98 Million ≈ $8.78 Million |
-- |
About Shandong Sito Bio-technology Co Ltd
Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, bis-decyl alcohol (BA), neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, 16ß and 16… Read more